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Abstract 
Background: Nonsteroidal anti-inflammatory drugs are of vast therapeutic benefit in the treatment of different types 
of inflammatory conditions. 1,2,3-Triazoles and their derivatives have a wide range of applications as anti-bacterial, 
anti-fungal, anti-tubercular, cytostatic, anti-HIV, anti-allergic, anti-neoplastic and anti-inflammatory (AI) agents. Consid-
ering the individual biological and medicinal importance of ibuprofen and 1,2,3-triazoles, we wanted to explore novel 
chemical entities based on ibuprofen and triazole moieties towards their biological significance.
Results: Click chemistry has utilized as an ideal strategy to prepare novel ibuprofen-based 1,4-disubstituted 1,2,3-tria-
zole containing molecules. These compounds were screened for their in vivo AI activity, among all the synthesized 
analogues 13o was shown potent effect than the reference AI drug ibuprofen at the same concentration (10 mg/
kg body weight). Compounds 13l, 13g, 13c, 13k, 13i, 13n, 13m and 13j were shown significant AI activity. These 
triazole analogues were also screened for their bactericidal profile. Compounds 13c, 13i, 13l and 13o exhibited con-
siderable bactericidal activity against gram positive and gram negative strains. In addition to this, molecular docking 
studies were also carried out into cyclooxygenase-2 active site to predict the affinity and orientation of these novel 
compounds (13a–q).
Conclusions: In summary, we have designed and synthesized 1,2,3-triazole analogues of ibuprofen in good yields 
using Click chemistry approach. AI and bactericidal activities of these compounds were evaluated and shown remark-
able results.
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Background
The nonsteroidal anti-inflammatory drugs are extensively 
applied for the treatment of analgesic, antipyretic, rheu-
matic arthritis and in high doses these are used to treat 
inflammatory diseases. Prolonged oral administration of 
these drugs was reported for frequent adverse effects on 
the gastrointestinal tract (GIT) (Allison et al. 1992; Laz-
zaroni and Bianchi Porro 2004) and subsequently leads 
to obstacles such as kidney damage (Ruiz and Lowen-
thal 1997), gastric ulcer (Alsarra et al. 2010) and hepato-
toxicity (Tan et  al. 2007). This is most likely due to the 
presence of free carboxyl group on Nonsteroidal anti-
inflammatory drugs (NSAIDs) (Mishra et  al. 2008). The 
GIT mucosal injury problems produced by NSAIDs are 
commonly believed to be caused by two different mecha-
nisms. One is local irritation produced by free carboxylic 
acid group and inhibition of prostaglandin biosynthesis 
in the GIT. The second has indirect effect can be attrib-
uted to combination of an ion trapping mechanism of 
NSAIDs from the lumen into the mucosa. Thus, free 
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acidic group plays a key role in keeping the effectiveness 
and producing the gastric ulceration as well. Hence, there 
remains a compelling need for effective NSAIDs with 
an improved safety profile and strategy for suppressing 
inflammation with least side effects.
It has been reported (Kalgutkar et  al. 2000a, b, 2002; 
Shanbhag et al. 1992; Tozkoparan et al. 2000) that conver-
sion of the carboxyl group containing NSAIDs to ester, 
amide functions and some other modifications retains 
the anti-inflammatory activity of the parent NSAIDs and 
makes them more selective towards cyclooxygenase-2 
(COX-2) enzyme. These modifications were inspired us 
to concentrate on the carboxyl side chain of ibuprofen 
to design novel class of molecules. During the synthesis 
of these analogues, we planned to utilize Click chemistry 
as key reaction. Click reaction is one of the most popu-
lar reactions for the construction of triazoles. Concept 
of this reaction discovered by the groups of Sharpless 
(Rostovtsev et al. 2002) and Meldal (Tornøe et al. 2002) 
independently. It is a copper(I)-catalyzed 1,3-dipolar 
cycloaddition (CuAAC) reaction which involves alkyne 
and azide as key partners to deliver 1,2,3-triazoles. Click 
chemistry has recently emerged to become a powerful 
tool in drug discovery. The 1,4-disubstituted 1,2,3-tria-
zoles obtained from CuAAC reactions are found to pos-
sess wide applications in several research fields including 
synthetic organic (Liu et  al. 2008; Wacharasindhu et  al. 
2009), biological (Romeo et  al. 2015) and medicinal 
chemistry (Liang et  al. 2015). 1,2,3-Triazole is one of 
the key structural unit found in a wide variety of bioac-
tive molecules tazobactam (Yang et al. 1999), cefatrizine 
(Dunn et  al. 1976), carboxyamidotriazole (Guo et  al. 
2008).
In this paper, we framed out our studies to synthesize 
analogues of ibuprofen, a widely used drug among other 
clinically existing NSAIDs. Free carboxyl group in ibupro-
fen could be modified to obtain more potent analogues. 
Derivatives of ibuprofen with modified carboxylic acid 
functionality were shown in Fig.  1 (1–3) (Bansal et  al. 
2015; Yadav et al. 2006). In compound 1, carboxyl group 
modified as an aromatic motif. Whereas in compounds 
2–3, acid functionality diminished by making different 
substituted aromatic amides. Interestingly, we found that 
some molecules having 1,2,3-triazoles (4–6, Fig.  1) (Rao 
et al. 2014; Haftchenary et al. 2015; Shafi et al. 2012) also 
showed good anti-inflammatory properties. Consider-
ing the individual biological activities, medicinal impor-
tance of ibuprofen and 1,4-disubstituted 1,2,3-triazoles, 
we designed novel class of small molecules (7, Fig.  2) 
having these two pharmacophores in single frame work 
through an aromatic linker. Resorcinol could be a useful 
moiety to link ibuprofen and 1,2,3-triazoles via C–C and 
C–O bonds respectively. The more active position (4th) of 
resorcinol was linked to carboxyl group of ibuprofen via 
C–C bond to obtain a novel compound which having ibu-
profen as a major structural backbone and key resorcinol 
moiety. We utilized more reactive hydroxyl functionality, 
which is present at para position of the linker to make the 
Fig. 1 Examples of COX-2 inhibitors/anti-inflammatory molecules containing ibuprofen and triazole moieties
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propargyl handle. Using Click chemistry approach, this 
was further diversified by treating with different azides 
to give novel analogues that contain ibuprofen, resorcinol 
and 1,4-disubstituted 1,2,3-triazoles as substructures.
In recent years, the multidrug resistance of microbial 
pathogens has heightened the urgency to develop new 
antibacterial agents. Having the advantages of mono 
therapy of an anti-inflammatory drug with anti-microbial 
properties, here we studied bactericidal activity along 




As shown in Scheme  1, 1-(2,4-dihydroxyphenyl)-2-(4-
isobutylphenyl)propan-1-one (10) was prepared by heat-
ing of resorcinol (9) and ibuprofen (8) in the presence of 
freshly fused ZnCl2. For O-alkylation, compound 10 was 
refluxed with propargyl bromide and potassium carbon-
ate in dry acetone for 8  h. In this reaction we got para 
propargylated compound (11) as major product with 
85  % yield. The reason for formation of para propar-
gylated product as major may be explained on the basis of 
mesomeric effect and steric factors; ortho hydroxy group 
will have less nucleophilicity than para hydroxyl group. 
Major product (11) was separated and analyzed by 1H-
NMR spectroscopy, which showed characteristic singlet 
at δ 12.91 due to presence of chelated phenolic hydrogen 
of ortho hydroxyl group and singlet for two protons at δ 
4.66 (O–CH2–), triplet for one proton at δ 2.53 (≡CH) 
indicates the formations of O-propargylation. With this 
evidence it is confirmed that the resulting major product 
was 1-(2-hydroxy-4-(prop-2-yn-1-yloxy)phenyl)-2-(4-
isobutylphenyl)propan-1-one (11).
Then we synthesized various aliphatic and aromatic 
azides (12a–q, Fig.  3) by utilizing literature protocols 
(Lee et  al. 2012; Kumar et  al. 2014). To prepare alkyl 
azides, corresponding alkyl halide was heated at 80–90 °C 
with NaN3 in DMF. Aromatic azides were prepared from 
different substituted anilines using diazotization followed 
by treatment with NaN3.
Fig. 2 Design of novel molecules 7 from 1 and 5 containing ibupro-
fen-aromatic linker-triazole moieties and their key disconnections
Scheme 1 Synthesis of 1-(4-((1H-1,2,3-triazol-4-yl)methoxy)-2-hydroxyphenyl)-2-(4-isobutylphenyl)propan-1-one derivatives 13a–q
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1,3-diploar cycloaddition between 1-(2-hydroxy-4-
(prop-2-yn-1-yloxy)phenyl)-2-(4-isobutylphenyl)-pro-
pan-1-one (11) and various aromatic, aliphatic azides 
(12a–q) produced seventeen novel 1,4-disubstituted 
1,2,3-triazoles in good to excellent yields (13a–q, Fig. 4). 
All the synthesized compounds were thoroughly ana-
lyzed by 1H-NMR, 13C-NMR and LRMS analytical 
techniques. Purity was determined by HPLC using the 
condition specified in each case: column, mobile phase, 
flow rate (Additional file 1).
Biological study
In vivo anti‑inflammatory activity
The in vivo anti-inflammatory activity of the synthesized 
novel triazole moiety containing molecules (13a–q) was 
determined at the dose of 10  mg/kg body weight using 
carrageenan-induced rat paw edema model (Winter 
et  al. 1962). Anti-inflammatory activity was calculated 
at hourly intervals up to 6  h after injection and results 
were summarized in Table  1 as the mean  ±  SEM paw 
volume (mL) and the percentage anti-inflammatory 
activity. The paw volume differences were compared 
between the treated animals and the control group. Per-
centage inhibition was calculated as per the formula, % 
inhibition =  [(Vo − Vt)/Vo] × 100, where Vo =  volume 
of the paw control at time t, Vt = volume of the paw of 
drug treated at time t. The maximum anti-inflammatory 
activity was obtained after 3 h which is the time required 
for reaching the maximum activity, soon after gradually 
decreased for the next 2 h.
Compounds 13a–q, showed mild to excellent anti-
inflammatory activities (47.00–94.01  % at 3  h, 55.47–
96.35 % at 4 h and 56.87–95.62 % at 5 h). It is interesting 
to note that presence of electron withdrawing group or 
atom (NO2 or Cl) at meta or para (C3 or C4) positions 
of benzyl or phenyl ring on triazole leads to significant 
increase in the activity. Among these triazoles (13a–q), 
compound 13o bearing a 4-nitrobenzyl group on the 
triazole moiety exhibited most potent activity 94.01 % at 
3 h, 96.35 % at 4 h, 95.62 % at 5 h and 94.17 % at 6 h with 
compare to reference drug (93.16 % at 3 h, 95.62 % at 4 h, 
95.62 % at 5 h and 94.70 % at 6 h). Compound 13l bear-
ing a 4-nitrophenyl group on the triazole moiety showed 
good anti-inflammatory activity of 90.59 % at 3 h, 93.43 % 
at 4 h and 93.12 % at 5 h. The 1,4-disubstituted 1,2,3-tria-
zole nucleus bearing phenyl (13g), 4-chloro phenyl (13c) 
were shown considerable inhibition of edema 91.24 
and 87.59  % respectively at 4  h. Moderate activity was 
observed with respect to compounds 13k (86.13 %), 13i 
(85.40 %), 13n (84.67 %) and 13m (81.02 %) at 4 h.
Bactericidal activity
According to the results obtained, all the bacterial strains 
noticed high susceptible nature towards the compounds 
tested. Among the tested triazoles, compounds 13c, 
13i, 13l and 13o exhibited high bactericidal activity. 
The minimum inhibitory concentration (MIC) of 13o 
against tested bacterial strains is comparable with that 
from standard antibiotic drug cefixime (Table 2). On the 
other hand, compounds 13l, 13c and 13i also produced 
significant MIC and minimum bactericidal concentration 
(MBC) values against tested human pathogenic organ-
isms. These results indicates that electron withdrawing 
group or atom (NO2 or Cl) at meta or para positions of 
benzyl or phenyl ring attached to triazole may increas-
ing the bactericidal activity than aliphatic and electron 
donating aryl substituted triazoles. By the present inves-
tigation, it has been understood that the synthesized 
compounds are highly active against gram positive strain 
compared to gram negative strains. Among the screened 
bacterial strains methicillin-resistant Staphylococcus 
aureus (MRSA) was found most susceptible MIC (12.5) 
and MBC (15.1) values for compound 13o which were 
almost nearer to the values <13.5 and <13 of positive 
control.
Molecular modeling approach
The successful docking has been performed for all newly 
synthesized target compounds (13a–q) using genetic 
optimization for ligand docking (GOLD) algorithm ver-
sion 2.0 (Verdonk et al. 2003). The GOLD program uses 
a genetic algorithm (GA) to explore the full range of the 
rotational flexibility of selected receptor hydrogens and 
ligand flexibility. The 3D crystallographic structure of 
COX-2 (PDB code 4PH9) (Orlando et al. 2015) was used 
as template selected from RCSB protein data bank (PDB) Fig. 3 Different aliphatic and aromatic azides (12a–q)
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for anti-inflammatory activity. The interactions between 
ligand (13a–q) and receptor in the modeled complexes 
were investigated and observed the fitness function abil-
ity of COX-2 by all newly synthesized inhibitors. The 
observed Chem score and Gold fitness scores have been 
produced in Tables  3 and 4. Binding energies shown in 
Table 5 were calculated with ArgusLab (Thompson 2004) 
docking software. Discovery studio visualizer has been 
utilized to visualize the binding conformations of these 
analogues in the active site of 4PH9 protein and good 
binding orientation poses were shown in Figs. 5, 6 and 7.
Among several residues of the active site region of 
COX-2, TYR356 and ARG121 allows an important role 
of formation of hydrogen bonds, which favors interac-
tion with COX-2 inhibitor. Molecular binding pattern 
of ibuprofen with COX-2 revealed that it has hydrogen 
bonds with ARG121 (bonding distances of 3.01, 2.97 Å) 
and TYR356 (bonding distances of 2.42, 5.21 Å) shown 
Fig. 4 Derivatives of target compound (13a–q)
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in Fig. 5. Similarly 13o also formed hydrogen bonds with 
bond distances viz. 2.91, 2.95 Å for ARG121 and 4.10 Å 
for TYR356 shown in Fig. 6. It is also forming hydrogen 
bonds with VAL89, LEU360, LEU93, VAL117, VAL350, 
LEU353, LEU385, MET523, TYR386, TRP388, PHE519, 
ILE113, VAL524, ALA528 and GLY527. These interac-
tions of 13o in the COX-2 active site may be driving to 
have more activity. Compound 13o has the highest fit-
ness score 70.31 and good Chem score 35.66 with bind-
ing energy −15.4749 compared with the fitness score 
41.19, Chem score 21.39 and binding energy −13.3519 of 
the standard drug ibuprofen (Tables 3, 4, 5). Compound 
13l established hydrogen bonds viz; 2.69, 4.53, 5.42 Å for 
ARG121 and 3.87, 4.27 Å for TYR356. It is also formed 
hydrogen bonds with LEU93, PHE358, VAL89, ILE113, 
TRP100, PHE358, VAL117, MET114 and TYR116 
(Fig.  7). Compound 13l showed fitness score 54.78 and 
Chem score 38.17 with binding energy −14.1561.
In this investigation, we discovered that the synthesized 
triazoles which showed good Chem score and Gold score 
functions, also exhibited good binding energy values. 
Finally, molecular docking studies showed good correla-
tion between the in vivo anti-inflammatory activity of final 
compounds and their binding interactions with COX-2 as 
well as their Gold fitness scores. Among all compounds, 




Melting points were determined in open capillaries. 
1H-Nuclear magnetic resonance (NMR) spectra were 
recorded on Bruker AV 300 and 400  MHz instruments, 
in CDCl3 using TMS as an internal standard. Chemical 
shifts are given in (δ) ppm and coupling constants (J) are 
given in Hz. Combinations of the following abbreviations 
are used to describe NMR spectra: s = singlet; d = dou-
blet; t =  triplet; q = quartet; m = multiplet. Thin layer 
chromatography (TLC) was carried out on aluminium 
sheets coated with silica gel 60 F254 (Merck, 1.05554) 
and the spots were visualized with UV light at 254  nm 
or alternatively by staining with aqueous basic potas-
sium permanganate. Flash column chromatography was 
performed using silica gel (Merck, 60A, 100–200 mesh). 
Chromatographic purity by HPLC was determined by 
using area normalization method and the condition 
specified in each case: column, mobile phase, flow rate, 
detection wavelength, and retention times. Commercially 
Table 1 In vivo anti-inflammatory activity of novel 1,2,3-triazoles (13a–q)
a P < 0.001 and b P < 0.01. Control (−) (0.1 mL of saline solution)
c Values are expressed as mean ± SEM from six observations and data is analyzed by one way ANOVA followed by Dunnett’s ‘t’ test
d Values in parentheses [percentage anti-inflammatory activity (% AI)]
Compound 3 h 4 h 5 h 6 h
Swelling Inhibition (%) Swelling Inhibition (%) Swelling Inhibition (%) Swelling Inhibition (%)
Volume of edemac (mL) and % AId
Control (−) 1.17 ± 0.032 1.37 ± 0.012 1.60 ± 0.019 1.89 ± 0.009
Ibuprofen 0.08 ± 0.021 93.16 0.06 ± 0.027 95.62 0.07 ± 0.027 95.62 0.10 ± 0.021 94.70
13a 0.60 ± 0.015 48.17 0.60 ± 0.004 56.20 0.66 ± 0.004 58.75 0.71 ± 0.012 62.43
13b 0.62 ± 0.024a 47.00 0.61 ± 0.008a 55.47 0.69 ± 0.008a 56.87 0.74 ± 0.016a 60.84
13c 0.17 ± 0.020 85.47 0.17 ± 0.016 87.59 0.21 ± 0.009 86.87 0.26 ± 0.011 86.24
13d 0.50 ± 0.007 57.26 0.49 ± 0.019 64.23 0.54 ± 0.009 66.25 0.56 ± 0.015 70.37
13e 0.43 ± 0.011 63.24 0.42 ± 0.023 69.34 0.53 ± 0.013 66.87 0.62 ± 0.018 67.19
13f 0.54 ± 0.015 53.84 0.54 ± 0.010 60.58 0.57 ± 0.019 64.37 0.62 ± 0.011 67.19
13g 0.15 ± 0.017a 87.17 0.12 ± 0.007a 91.24 0.15 ± 0.014a 90.62 0.20 ± 0.012a 89.41
13h 0.40 ± 0.022 65.81 0.49 ± 0.012 64.23 0.56 ± 0.017 65.00 0.60 ± 0.011 68.25
13i 0.23 ± 0.009b 80.34 0.20 ± 0.019b 85.40 0.26 ± 0.010b 83.75 0.31 ± 0.016b 83.59
13j 0.32 ± 0.012b 72.64 0.34 ± 0.023b 75.18 0.40 ± 0.013b 75.00 0.49 ± 0.011b 74.07
13k 0.20 ± 0.010b 82.90 0.19 ± 0.016b 86.13 0.25 ± 0.012b 84.37 0.30 ± 0.020b 84.20
13l 0.11 ± 0.019a 90.59 0.09 ± 0.011a 93.43 0.11 ± 0.021a 93.12 0.16 ± 0.012a 91.53
13m 0.27 ± 0.024b 76.92 0.26 ± 0.020b 81.02 0.32 ± 0.011b 80.00 0.42 ± 0.017b 77.77
13n 0.25 ± 0.006b 78.63 0.21 ± 0.012b 84.67 0.27 ± 0.021b 83.12 0.35 ± 0.009b 81.48
13o 0.07 ± 0.011a 94.01 0.05 ± 0.021a 96.35 0.07 ± 0.011a 95.62 0.11 ± 0.014a 94.17
13p 0.36 ± 0.010 69.23 0.40 ± 0.015 70.80 0.47 ± 0.010 70.62 0.52 ± 0.012 72.48
13q 0.38 ± 0.019 67.52 0.45 ± 0.019 67.15 0.26 ± 0.049b 67.50 0.58 ± 0.020 69.31
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Table 2 MIC/MBC (µg/mL) values of synthesized compounds (13a–q) and Cefixime against tested bacterial strains
MRSA, Methicillin-resistant Staphylococcus aureus, B. subtilis, Bacillus subtilis, B. cereus, Bacillus cereus, E. coli, Escherichia coli, K. pneumoniae, Klebsiella pneumonia,  
P. Vulgaris, Proteus vulgaris
Compounds Gram positive Gram negative
MRSA B. subtilis B. cereus E. coli K. pneumoniae P. vulgaris
MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC
13a >150 >155 109.3 112 118 120 98.6 100 >130 >140 >90 >90
13b 120 126 88.2 >90 102 108 92.6 100 >128 >140 >100 >110
13c 24.1 27.3 28.9 >40 32.0 42.1 28.6 30.2 38.5 >40 >50 >50
13d 30.6 31.6 >25 30.2 45.7 50.1 >40 42.3 62.8 65.2 78.3 80.2
13e 57.9 60.0 60.5 70.2 79.6 82.1 >120 >120 >100 105.1 >150 >150
13f >170 >170 >180 >180 88.1 90.2 112 117 136 138 80.3 85
13g 40.5 42.3 66.6 70.5 >60 68.0 55.3 55.5 33.8 36.9 90.1 >100
13h >118 >120 >140 >140 114 117 >130 <135 175 179 <200 <200
13i 20.5 22.1 18.6 19.3 25.8 30.3 22.5 25.8 35.9 38.0 45.0 >50
13j >188 >190 >153 >160 >160 >160 112 113 >145 >148 >170 >172
13k 33.6 >40 35.9 47.0 44.6 50.2 >50 66.0 58.2 65.0 >80 >86
13l 18.5 24.9 20.5 22.8 20.7 21.0 18.2 24.1 33.6 35.1 30.9 33.5
13m >189 >200 >168 >170 159 163 149 156 177 180 161 164
13n 36.3 39.5 58.0 >80 >60 >75 >50 58.6 80.2 92.0 >70 >85
13o 12.5 15.1 12.9 13.0 12.0 12.0 15.5 20.3 25.3 >30 28.4 >35
13p >120 >120 98.9 102 >140 >150 80.6 92.8 >100 >120 >150 >165
13q >125 >130 >155 158 >160 >160 >110 >115 146 148 133 134
Cefixime <13.5 <13 10.2 11.0 10 10 13.0 13 17 17.2 20.6 21.0
Table 3 Chem score of novel 1,2,3-triazoles (13a–q)
Chem score = ΔGbinding + Pclash + CinternalPinternal + (CcovalentPcovalent + Pconstraint)
Score = −[DG + DE(clash) + DE(int)]
Compound Score DG S(hbond) S(metal) S(lipo) DE(clash) DE(int)
13a 33.75 −38.96 1.77 0.00 290.03 0.79 4.43
13b 32.60 −36.75 2.67 0.00 244.12 0.75 3.40
13c 40.43 −45.28 1.94 0.00 342.10 0.75 4.10
13d 33.17 −37.99 2.69 0.00 251.40 2.10 2.72
13e 36.23 −40.09 3.56 0.00 246.17 0.11 3.75
13f 31.89 −35.41 2.70 0.00 229.21 0.09 3.43
13g 38.65 −42.06 3.58 0.00 257.62 1.20 2.20
13h 36.19 −40.46 3.52 0.00 246.84 2.42 1.85
13i 38.03 −42.37 3.58 0.00 260.74 1.87 2.47
13j 36.76 −40.21 2.34 0.00 277.60 0.28 3.18
13k 38.84 −41.32 2.98 0.00 267.56 0.08 2.40
13l 38.17 −41.17 1.94 0.00 297.19 0.47 2.52
13m 33.96 −40.00 2.91 0.00 265.74 2.71 3.32
13n 35.60 −39.63 2.61 0.00 271.34 0.05 3.99
13o 35.66 −38.89 2.39 0.00 277.42 0.46 2.76
13p 39.07 −47.49 2.12 0.00 346.07 3.77 4.65
13q 38.39 −42.34 3.52 0.00 261.98 0.56 3.39
Ibuprofen 21.39 −22.32 2.05 0.00 132.11 0.10 0.84
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available reagents were used as supplied and some of 
them were distilled before use. All reactions were per-
formed in oven dried glassware. All solvents were 
removed by evaporation under reduced pressure.
General procedure for the synthesis 
of 1‑(2,4‑dihydroxyphenyl)‑2‑(4‑isobutylphenyl)
propan‑1‑one (10)
Ibuprofen (2  g, 9.69  mmol) was added to fused zinc 
chloride (1.98  g, 14.54  mmol) and heated to 120  °C for 
20  min then resorcinol (1.06  g, 9.69  mmol) was added. 
The reaction mixture was heated to 140  °C for 30  min 
and monitored by TLC for complete conversion of start-
ing materials. The reaction mixture was allowed to room 
temperature and was poured into ice cold water (100 mL), 
extracted with ethyl acetate (3 × 50 mL). The combined 
organic layers were washed with 5  % HCl (50  mL), sat-
urated NaHCO3 (25  mL) and brine (2  ×  25  mL). The 
organic layer was dried over anhydrous sodium sulphate, 
filtered and concentrated in vacuo. The crude product 
was purified by column chromatography using 100–200 
mesh silica gel, eluted at 10 % ethyl acetate in pet ether 
to afford 1-(2,4-dihydroxy-phenyl)-2-phenyl-ethanone as 
light yellow liquid (2.2 g, 75 %).
Chemical formula: C19H22O3; 1H-NMR (400  MHz, 
CDCl3) δ 12.97 (s, 1H), 7.70 (d, J = 8.82 Hz, 1H), 7.22–
7.16 (m, 2H), 7.12–7.06 (m, 2H), 6.33 (d, J  =  2.30  Hz, 
1H), 6.28 (dd, J = 8.78, 2.32 Hz, 1H), 4.60 (q, J = 6.79 Hz, 
1H), 2.44–2.39 (m, 2H), 1.88–1.77 (m, 1H), 1.51 (d, 
J  =  6.82  Hz, 3H), 0.88 (m, 6H); 13C-NMR (100  MHz, 
CDCl3) δ 205.3, 166.1, 163.2, 141.3, 139.3, 133.6, 130.5 
(2C), 128.1 (2C), 114.0, 108.9, 104.6, 48.1, 46.6, 31.9, 24.2 
(2C), 21.0; LRMS: (ES+) m/z = 299 [M + 1].
General procedure for the synthesis of 1‑(2‑hydroxy‑4‑(prop‑
2‑yn‑1‑yloxy)phenyl)‑2‑(4‑isobutylphenyl)propan‑1‑one (11)
Compound (10) (2.1  g, 7.038  mmol) was taken in dry 
acetone, anhydrous K2CO3 (0.972  g, 7.038  mmol) and 
propargyl bromide (0.837  g, 7.038, mmol) was added. 
This reaction mixture was refluxed for 8  h. Progress of 
the reaction was monitored by TLC, the reaction mix-
ture was cooled to room temperature and solvent was 
removed in vacuo, then diluted with water (50  mL) and 
extracted with ethyl acetate (3 × 50 mL). The combined 
organic layers were washed with brine (2 × 25 mL). The 
organic layer was dried over anhydrous sodium sulphate, 
filtered and concentrated in vacuo. The crude product was 
purified by column chromatography using 100–200 mesh 
silica gel, eluted at 5 % ethyl acetate in pet ether to afford 
1-(2-hydroxy-4-(prop-2-yn-1-yloxy)phenyl)-2-(4-isobu-
tylphenyl)propan-1-one as light yellow liquid (2 g, 85 %).
Chemical formula: C22H24O3; 1H-NMR (400  MHz, 
CDCl3) δ 12.91 (s, 1H), 7.73 (d, J  =  9.04  Hz, 1H), 
7.20–7.17 (m, 2H), 7.08 (d, J  =  8.00  Hz, 2H), 6.48 (d, 
J = 2.48 Hz, 1H), 6.40 (dd, J = 9.00, 2.51 Hz, 1H), 4.66 (s, 
2H), 4.64–4.57 (m, 1H), 2.53 (t, J = 2.32 Hz, 1H), 2.41 (d, 
J = 7.18 Hz, 2H), 1.82 (m, 1H), 1.51 (d, J = 6.86 Hz, 3H), 
0.87 (d, J = 6.60 Hz, 6H); 13C-NMR (75 MHz, CDCl3) δ 






13a 45.77 1.16 43.59 0.00 −15.31
13b 57.40 7.50 47.91 0.00 −15.97
13c 54.17 4.29 56.67 0.00 −28.04
13d 55.57 12.48 44.01 0.00 −17.43
13e 51.45 5.51 44.29 0.00 −14.96
13f 58.76 7.97 46.45 0.00 −13.09
13g 60.01 6.00 48.17 0.00 −12.22
13h 56.08 9.08 47.70 0.00 −10.33
13i 56.08 4.69 47.22 0.00 −13.53
13j 55.11 7.17 45.42 0.00 −14.52
13k 52.03 5.07 44.07 0.00 −13.63
13l 54.78 6.10 49.52 0.00 −19.42
13m 62.06 13.54 51.06 0.00 −21.69
13n 60.05 10.71 48.89 0.00 −17.88
13o 70.31 13.07 53.66 0.00 −16.55
13p 53.70 6.05 48.38 0.00 −18.86
13q 53.01 4.73 45.93 0.00 −14.87
Ibuprofen 41.19 5.84 27.89 0.00 −3.00
Table 5 ArgusLabs binding energy values of  novel 
1,2,3-triazoles (13a–q)









13a −13.2381 22 −12.0907 21
13b −12.3289 86 −8.0643 21
13c −15.5507 18 −11.4343 25
13d −13.9083 19 −11.899 19
13e −13.4295 26 −11.7591 17
13f −13.2227 16 −1.36602 16
13g −15.0759 14 −13.2652 21
13h −12.3786 16 −14.1789 19
13i −15.9765 17 −9.5211 19
13j −14.9881 11 −15.6249 19
13k −14.1346 14 −13.3685 19
13l −14.1561 12 +3.0948 17
13m −14.1131 15 −12.7818 18
13n −14.9852 14 −12.7541 17
13o −15.4749 10 −11.1716 20
13p −12.1776 7 −12.5944 20
13q −8.1178 7 −8.7334 19
Ibuprofen −13.3519 6 −4.82611 8
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206.0, 166.7, 162.7, 141.6, 139.3, 133.6, 130.3 (2C), 128.7 
(2C), 114.5, 110.1, 105.1, 78.8, 76.8, 57.0, 48.1, 46.9, 31.4, 
24.2 (2C), 20.0; LRMS: (ES+) m/z =  337 [M +  1], 359 
[M + Na].
General procedure for the synthesis of 1,4‑disubstituted 
1,2,3‑triazole analogues (13a–q)
Propargyl derivative (11) (100  mg, 0.297  mmol) is dis-
solved in 5  mL aqueous t-BuOH (50  %) was added 
CuSO4. 5H2O (5  mol%) followed by sodium ascor-
bate (10 mol%) and azide (0.356 mmol) was added. The 
reaction mixture was stirred for 1  h at room tempera-
ture, monitored by TLC. After complete conversion of 
starting materials the reaction mixture was diluted with 
water (25 mL), extracted with ethyl acetate (3 × 25 mL). 
The combined organic layers were washed with brine 
(2 × 25 mL). The organic layer was dried over anhydrous 
sodium sulphate, filtered and concentrated in vacuo. The 
crude product was purified by column chromatography 
using 100–200 mesh silica gel and ethyl acetate in pet 
ether to afford corresponding 1,4-disubstituted 1,2,3-tri-
azole analogues.
Fig. 5 Docking pose of ibuprofen into the COX-2 (4PH9) active site. Hydrogen bonds are shown in dotted lines
Fig. 6 Docking pose of compound 13o into the COX-2 (4PH9) active site. Hydrogen bonds are shown in dotted lines
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1‑(2‑Hydroxy‑4‑((1‑octyl‑1H‑1,2,3‑triazol‑4‑yl)methoxy)
phenyl)‑2‑(4‑isobutylphenyl)propan‑1‑one (13a)
Chemical formula: C30H41N3O3; yield: 85 %; white solid; 
mp: 84–86  °C; 1H-NMR (300  MHz, CDCl3) δ 12.91 
(s, 1H), 7.75 (d, J =  9.03  Hz, 1H), 7.59 (s, 1H), 7.21 (d, 
J  =  8.04  Hz, 2H), 7.10 (d, J  =  8.03  Hz, 2H), 6.52 (d, 
J =  2.44 Hz, 1H), 6.46 (dd, J =  8.95, 2.49 Hz, 1H), 5.22 
(s, 2H), 4.64 (q, J =  6.85  Hz, 1H), 4.37 (t, J =  7.27  Hz, 
2H), 2.45 (d, J =  7.15  Hz, 2H), 1.96–1.81 (m, 3H), 1.55 
(d, J  =  6.84  Hz, 3H), 1.32–1.27 (m, 9H), 0.94–0.9 (m, 
10H); 13C-NMR (75 MHz, CDCl3) δ 205.1, 166.5, 165.0, 
143.9, 141.5, 139.5, 133.2, 130.8 (2C), 128.3 (2C), 123.7, 
114.5, 108.9, 103.6, 64.0, 52.5, 48.6, 47.1, 33.9, 32.5, 32.4, 
31.3, 31.2, 28.8, 25.0, 24.8 (2C), 21.6, 16.5; LRMS: (ES+) 
m/z = 492 [M + 1], 514 [M + Na]; HPLC 98.03 %, col-
umn: phenomenex luna C8 (2) (250X4.6  mm), mobile 





Chemical formula: C28H37N3O3; yield: 90 %; white solid; 
mp: 83–85  °C; 1H-NMR (300  MHz, CDCl3) δ 12.90 
(s, 1H), 7.72 (d, J =  8.97  Hz, 1H), 7.57 (s, 1H), 7.19 (d, 
J = 7.72 Hz, 2H), 7.08 (d, J = 7.68 Hz, 2H), 6.49 (s, 1H), 
6.43 (d, J = 8.87 Hz, 1H), 5.19 (s, 2H), 4.61 (q, J = 6.74 Hz, 
1H), 4.34 (t, J = 7.17 Hz, 2H), 2.41 (d, J = 7.07 Hz, 2H), 
1.96–1.76 (m, 3H), 1.51 (d, J =  6.73  Hz, 3H), 1.26–1.35 
(m, 6H), 0.91–0.84 (m, 9H); 13C-NMR (75 MHz, CDCl3) δ 
205.2, 166.5, 164.9, 143.9, 141.5, 139.5, 133.3, 130.8 (2C), 
128.3 (2C), 123.8, 114.5, 108.9, 103.6, 64.0, 52.5, 48.6, 
47.1, 33.4, 32.5, 32.4, 28.5, 24.8 (3C), 21.6, 16.4; LRMS: 
(ES+) m/z = 464 [M + 1], 486 [M + Na]; HPLC 99.12 %, 
column: phenomenex luna C8 (2) (250X4.6 mm), mobile 





Chemical formula: C28H28ClN3O3; yield: 81  %; white 
solid; mp: 79–81  °C; 1H-NMR (400  MHz, CDCl3) 
δ 12.92 (s, 1H), 8.01 (s, 1H), 7.74 (d, J =  9.07  Hz, 1H), 
7.68 (d, J = 8.82 Hz, 2H), 7.50 (d, J = 8.85 Hz, 2H), 7.19 
(d, J =  8.04 Hz, 2H), 7.08 (d, J =  8.04 Hz, 2H), 6.53 (d, 
J =  2.48 Hz, 1H), 6.45 (dd, J =  8.99, 2.51 Hz, 1H), 5.28 
(s, 2H), 4.61 (q, J =  6.83  Hz, 1H), 2.41 (d, J =  7.17  Hz, 
2H), 1.87–1.77 (m, 1H), 1.52 (d, J = 6.84 Hz, 3H), 0.87 (d, 
J = 6.53 Hz, 6H); 13C-NMR (126 MHz, CDCl3) δ 205.1, 
166.2, 164.5, 144.7, 141.1, 139.1, 135.9, 135.4, 132.9, 130.6 
(2C), 130.4 (2C), 127.9, 122.5 (2C), 121.7, 114.1, 108.3, 
103.0, 63.1, 47.9, 46.3, 31.5, 23.8 (2C), 20.7; LRMS: (ES+) 
m/z = 490 [M + 1]; HPLC 96.19 %, column: X-BRIDGE 
C-18 (150X4.6  mm), mobile phase A: 0.1  % farmic acid 
in water, mobile phase B: acetonitrile, gradient (T/%B): 





Chemical formula: C26H33N3O3; yield: 79 %; white solid; 
mp: 89–91  °C; 1H-NMR (400  MHz, CDCl3) δ 12.91 
(s, 1H), 7.73 (d, J =  8.77  Hz, 1H), 7.61 (s, 1H), 7.19 (d, 
J = 7.85 Hz, 2H), 7.08 (d, J = 7.82 Hz, 2H), 6.50 (s, 1H), 
6.45 (d, J = 8.68 Hz, 1H), 5.19 (s, 2H), 4.69–4.52 (m, 2H), 
2.41 (d, J  =  7.12  Hz, 2H), 1.98–1.77 (m, 3H), 1.57 (d, 
J = 6.41 Hz, 3H), 1.51 (d, J = 6.78 Hz, 3H), 0.91–0.83 (m, 
9H); 13C-NMR (100 MHz, CDCl3) δ 205.0, 165.8, 164.4, 
142.2, 140.5, 138.6, 132.2, 129.7 (2C), 127.2 (2C), 122.4, 
113.2, 107.5, 102.2, 62.3, 59.1, 46.5, 45.0, 30.3, 30.1, 22.4 





Chemical formula: C26H33N3O3; yield: 91 %; white solid; 
mp: 89–91  °C; 1H-NMR (400  MHz, CDCl3) δ 12.91 
(s, 1H), 7.72 (d, J =  9.03  Hz, 1H), 7.58 (s, 1H), 7.19 (d, 
J  =  7.94  Hz, 2H), 7.08 (d, J  =  7.91  Hz, 2H), 6.49 (d, 
J =  2.24 Hz, 1H), 6.43 (dd, J =  8.98, 2.29 Hz, 1H), 5.18 
(s, 2H), 4.61 (q, J =  6.74  Hz, 1H), 4.35 (t, J =  7.23  Hz, 
2H), 2.41 (d, J = 7.14 Hz, 2H), 1.92–1.78 (m, 3H), 1.51 (d, 
J = 6.82 Hz, 3H), 1.40–1.30 (m, 2H), 0.95 (t, J = 7.35 Hz, 
3H), 0.87 (d, J  =  6.56  Hz, 6H); 13C-NMR (101  MHz, 
Fig. 7 Docking pose of compound 13l into the COX-2 (4PH9) active 
site. Hydrogen bonds are shown in dotted lines
Page 11 of 15Angajala et al. SpringerPlus  (2016) 5:423 
CDCl3) δ 205.0, 165.8, 164.3, 143.0, 140.5, 138.6, 132.2, 
129.7 (2C), 127.2 (2C), 122.6, 113.2, 107.6, 102.2, 62.1, 
50.2, 46.5, 45.0, 32.2, 30.1, 22.4 (2C) 19.7, 19.2, 13.4; 
LRMS: (ES+) m/z = 436 [M + 1], 458 [M + Na]; HPLC 
99.31 %, column: phenomenex luna C8 (2) (250X4.6 mm), 




Chemical formula: C26H33N3O3; yield: 86 %; white solid; 
mp: 97–99  °C; 1H-NMR (400  MHz, CDCl3) δ 12.89 (s, 
1H), 7.80–7.48 (m, 2H), 7.30–7.00 (m, 4H), 6.58–6.35 
(m, 2H), 5.19 (d, J  =  0.52  Hz, 2H), 4.72–4.54 (m, 1H), 
4.25–4.08 (m, 2H), 2.52–2.11 (m, 3H), 1.81–1.51 (m, 
5H), 1.09–0.73 (m, 12H); 13C-NMR (101 MHz, CDCl3) δ 
205.0, 165.8, 164.3, 142.9, 140.5, 138.6, 132.2, 129.7 (2C), 
127.2 (2C), 123.1, 113.2, 107.6, 102.2, 62.1, 57.6, 46.5, 
45.0, 30.0, 29.6, 22.3 (2C), 19.8 (2C), 19.2; LRMS: (ES+) 
m/z = 436 [M + 1], 458 [M + Na]; HPLC 99.32 %, col-
umn: phenomenex luna C8 (2) (250X4.6  mm), mobile 




Chemical formula: C28H29N3O3; yield: 96 %; white solid; 
mp: 138–140 °C; 1H-NMR (500 MHz, CDCl3) δ 12.91 (s, 
1H), 8.04 (s, 1H), 7.76–7.71 (m, 3H), 7.53 (t, J = 7.77 Hz, 
2H), 7.45 (t, J = 7.40 Hz, 1H), 7.21 (d, J = 8.02 Hz, 2H), 
7.09 (d, J  =  8.00  Hz, 2H), 6.54 (d, J  =  2.46  Hz, 1H),), 
6.47 (dd, J  =  8.99, 2.48  Hz, 1H), 5.29 (s, 2H), 4.63 (q, 
J  =  6.81  Hz, 1H), 2.43 (d, J  =  7.16  Hz, 2H), 1.87–1.79 
(m, 1H), 1.54 (d, J = 6.84 Hz, 3H), 0.89 (d, J = 6.59 Hz, 
6H); 13C-NMR (126 MHz, CDCl3) δ 205.1, 166.3, 164.6, 
144.4, 141.1, 139.1, 137.4, 132.9, 130.4 (2C), 130.3 (2C), 
129.6, 127.9 (2C), 121.8, 121.3 (2C), 114.1, 108.3, 103.1, 
63.1, 47.8, 46.3, 31.5, 23.8 (2C), 20.7; LRMS: (ES+) 
m/z = 456 [M + 1], 478 [M + Na]; HPLC 99.28 %, col-
umn: X-BRIDGE C-18 (150X4.6  mm), mobile phase A: 
0.1 % farmic acid in water, mobile phase B: acetonitrile, 




Chemical formula: C29H31N3O3; yield: 83 %; white solid; 
mp: 126–128 °C; 1H-NMR (400 MHz, CDCl3) δ 12.92 (s, 
1H), 7.99 (s, 1H), 7.77–7.69 (m, 2H), 7.59 (d, J = 8.44 Hz, 
1H), 7.31 (d, J  =  8.15  Hz, 2H), 7.19 (d, J  =  8.07  Hz, 
2H), 7.08 (d, J  =  8.06  Hz, 2H), 6.53 (d, J  =  2.43  Hz, 
1H), 6.46 (dd, J =  9.01, 2.50  Hz, 1H), 5.27 (s, 2H), 4.62 
(q, J  =  6.84  Hz, 1H), 2.43–2.39 (m, 5H), 1.85–1.77 
(m, 1H), 1.51 (d, J = 6.85 Hz, 3H), 0.87 (d, J = 6.59 Hz, 
6H); 13C-NMR (126 MHz, CDCl3) δ 205.1, 166.3, 164.6, 
144.2, 141.1, 139.7, 139.2, 132.9, 130.9 (2C), 130.3 (2C), 
127.9 (2C), 121.8, 121.3, 121.2 (2C), 114.1, 108.4, 103.1, 
63.2, 47.8, 46.3, 31.5, 23.8 (2C), 22.5, 20.7; LRMS: (ES+) 
m/z = 470 [M + 1], 492 [M + Na]; HPLC 98.88 %, col-
umn: X-BRIDGE C-18 (150X4.6  mm), mobile phase A: 
0.1 % farmic acid in water, mobile phase B: acetonitrile, 





Chemical formula: C28H28ClN3O3; yield: 89  %; white 
solid; mp: 118–120  °C; 1H-NMR (400  MHz, CDCl3) δ 
12.92 (s, 1H), 8.04 (s, 1H), 7.78 (t, J = 1.8 Hz, 1H), 7.74 
(d, J  =  9.1  Hz, 1H), 7.65–7.61 (m, 1H), 7.48–7.40 (m, 
2H), 7.19 (d, J =  8.1  Hz, 2H), 7.08 (d, J =  8.0  Hz, 2H), 
6.52 (d, J =  2.5  Hz, 1H), 6.45 (dd, J =  9.0, 2.5  Hz, 1H), 
5.27 (s, 2H), 4.62 (q, J = 6.8 Hz, 1H), 2.41 (d, J = 7.1 Hz, 
2H), 1.86–1.76 (m, 1H), 1.51 (d, J = 6.8 Hz, 3H), 0.87 (d, 
J  =  6.6  Hz, 6H); 13C-NMR (126  MHz, CDCl3) δ 205.1, 
166.2, 164.5, 144.7, 141.1, 139.1, 138.2, 136.2, 132.9, 
131.5, 130.4 (2C), 129.7, 127.9 (2C), 121.8, 121.5, 119.2, 
114.1, 108.3, 103.0, 63.0, 47.8, 46.2, 31.5, 23.8 (2C), 20.7; 
LRMS: (ES+) m/z = 490 [M + 1], 512 [M + Na]; HPLC 
98.70 %, column: X-BRIDGE C-18 (150X4.6 mm), mobile 
phase A: 0.1 % farmic acid in water, mobile phase B: ace-
tonitrile, gradient (T/%B): 0/20, 3/20, 12/95, 23/95, 25/20, 




Chemical formula: C34H49N3O3; yield: 95 %; white solid; 
mp: 69–71  °C; 1H-NMR (400  MHz, CDCl3) δ 12.92 
(s, 1H), 7.72 (d, J =  9.05  Hz, 1H), 7.58 (s, 1H), 7.19 (d, 
J  =  7.92  Hz, 2H), 7.08 (d, J  =  7.89  Hz, 2H), 6.49 (d, 
J =  2.18 Hz, 1H), 6.43 (dd, J =  8.98, 2.21 Hz, 1H), 5.18 
(s, 2H), 4.61 (q, J =  6.72  Hz, 1H), 4.33 (t, J =  7.24  Hz, 
2H), 2.41 (d, J =  7.14  Hz, 2H), 1.93–1.78 (m, 3H), 1.51 
(d, J = 6.80 Hz, 3H), 1.33–1.23 (m, 19H), 0.90–0.85 (m, 
9H); 13C-NMR (101 MHz, CDCl3) δ 205.0, 165.8, 164.3, 
143.0, 140.5, 138.6, 132.2, 129.7 (2C), 127.2 (2C), 122.6, 
113.2, 107.6, 102.2, 62.1, 50.5, 46.5, 45.0, 31.9, 30.2, 30.1, 
29.6 (2C), 29.5, 29.3, 29.3, 28.9, 26.5, 22.7, 22.4, 22.4, 19.2, 
14.1; LRMS: (ES+) m/z =  548 [M +  1], 570 [M + Na]; 
HPLC 98.21  %, column: phenomenex luna C8 (2) 
(250X4.6 mm), mobile phase: 90 % acetonitrile in 0.1 % 
formic acid, flow rate: 1.0 mL/min.
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1‑(2‑Hydroxy‑4‑((1‑(3‑nitrophenyl)‑1H‑1,2,3‑triazol‑4‑yl)
methoxy)phenyl)‑2‑(4‑isobutylphenyl)propan‑1‑one (13k)
Chemical formula: C28H28N4O5; yield: 81 %; yellow solid; 
mp: 146–148  °C; 1H-NMR (400  MHz, CDCl3) δ 12.92 
(s, 1H), 8.60 (s, 1H), 8.31 (d, J =  8.11  Hz, 1H), 8.18 (d, 
J = 6.46 Hz, 2H), 7.80–7.70 (m, 2H), 7.19 (d, J = 7.90 Hz, 
2H), 7.08 (d, J = 7.88 Hz, 2H), 6.52 (d, J = 2.20 Hz, 1H), 
6.46 (dd, J  =  8.96, 2.24  Hz, 1H), 5.30 (s, 2H), 4.62 (q, 
J = 6.67 Hz, 1H), 2.41 (d, J = 7.13 Hz, 2H), 1.87–1.76 (m, 
1H), 1.51 (d, J = 6.79 Hz, 3H), 0.87 (d, J = 6.55 Hz, 6H); 
13C-NMR (101 MHz, CDCl3) δ 205.1, 165.8, 164.0, 148.9, 
144.7, 140.6, 138.5, 137.5, 132.3, 131.0, 129.7 (2C), 127.2 
(2C), 126.0, 123.4, 121.1, 115.3, 113.4, 107.5, 102.2, 61.8, 
46.6, 45.0, 30.1, 22.3 (2C), 19.2; LRMS: (ES+) m/z = 501 
[M + 1], 523 [M + Na]; HPLC 99.69 %, column: phenom-
enex luna C8 (2) (250X4.6 mm), mobile phase: 90 % ace-
tonitrile in 0.1 % formic acid, flow rate: 1.0 mL/min.
1‑(2‑Hydroxy‑4‑((1‑(4‑nitrophenyl)‑1H‑1,2,3‑triazol‑4‑yl)
methoxy)phenyl)‑2‑(4‑isobutylphenyl)propan‑1‑one (13l)
Chemical formula: C28H28N4O5; yield: 77  %; yellow 
solid; mp: 167–169  °C; 1H-NMR (400  MHz, CDCl3) 
δ 12.93 (s, 1H), 8.42 (d, J  =  9.0  Hz, 2H), 8.19 (s, 1H), 
7.99 (d, J =  9.0  Hz, 2H), 7.77 (d, J =  9.0  Hz, 1H), 7.21 
(d, J  =  8.0  Hz, 2H), 7.10 (d, J  =  8.0  Hz, 2H), 6.53 (d, 
J = 2.4 Hz, 1H), 6.46 (dd, J = 8.9, 2.4 Hz, 1H), 5.31 (s, 2H), 
4.63 (q, J = 6.8 Hz, 1H), 2.43 (d, J = 7.1 Hz, 2H), 1.88–
1.78 (m, 1H), 1.53 (d, J = 6.8 Hz, 3H), 0.89 (d, J = 6.6 Hz, 
6H); 13C-NMR (101 MHz, CDCl3) δ 205.1, 165.8, 163.9, 
147.3, 144.9, 140.9, 140.6, 138.5, 132.3, 129.7 (2C), 127.2 
(2C), 125.5 (2C), 120.9, 120.6 (2C), 113.5, 107.4, 102.2, 
61.8, 46.6, 45.0, 30.1, 22.4, 22.3 (2C), 19.2; LRMS: (ES+) 
m/z = 501 [M + 1]; HPLC 99.87 %, column: phenomenex 
luna C8 (2) (250X4.6 mm), mobile phase: 90 % acetoni-




Chemical formula: C28H35N3O3; yield: 89 %; white solid; 
mp: 118–120  °C; 1H-NMR (400  MHz, CDCl3) δ 12.92 
(s, 1H), 7.73 (d, J =  9.10  Hz, 1H), 7.60 (s, 1H), 7.19 (d, 
J  =  8.08  Hz, 2H), 7.08 (d, J  =  8.08  Hz, 2H), 6.50 (d, 
J = 2.50 Hz, 1H), 6.44 (dd, J = 9.00, 2.53 Hz, 1H), 5.18 (s, 
2H), 4.61 (q, J = 6.86 Hz, 1H), 4.45 (tt, J = 11.85, 3.85 Hz, 
1H), 2.41 (d, J  =  7.18  Hz, 2H), 2.25–2.17 (m, 2H), 
1.97–1.88 (m, 2H), 1.77 (m, 3H), 1.51 (d, J  =  6.87  Hz, 
3H), 1.49–1.39 (m, 2H), 1.33–1.23 (m, 2H), 0.87 (d, 
J = 6.61 Hz, 6H); 13C-NMR (126 MHz, CDCl3) δ 205.1, 
166.2, 164.8, 143.1, 141.1, 139.2, 132.8, 130.3 (2C), 127.9 
(2C), 121.3, 114.0, 108.4, 103.0, 63.3, 61.4, 47.8, 46.3, 34.9 
(2C), 31.5, 26.5 (2C), 26.5, 23.8 (2C), 20.7; LRMS: (ES+) 
m/z = 462 [M + 1]; HPLC 99.89 %, column: phenomenex 
luna C8 (2) (250X4.6 mm), mobile phase: 90 % acetoni-




Chemical formula: C27H33N3O3; yield: 82  %; white 
solid; mp: 130–132  °C; 1H-NMR (400  MHz, CDCl3) δ 
12.92 (s, 1H), 7.73 (d, J = 8.7 Hz, 1H), 7.60 (s, 1H), 7.19 
(d, J  =  8.0  Hz, 2H), 7.08 (d, J  =  8.0  Hz, 2H), 6.50 (d, 
J =  2.5  Hz, 1H), 6.44 (dd, J =  8.6, 2.5  Hz, 1H), 5.17 (s, 
2H), 4.96–4.88 (m, 1H), 4.61 (q, J = 6.84 Hz, 1H), 2.41 (d, 
J =  7.2  Hz, 2H), 2.31–2.21 (m, 2H), 2.09–1.99 (m, 2H), 
1.96–1.86 (m, 2H), 1.84–1.74 (m, 3H), 1.51 (d, J = 6.8 Hz, 
3H), 0.87 (d, J =  6.5  Hz, 6H); LRMS: (ES+) m/z =  448 
[M + 1], 470 [M + Na]; HPLC 99.37 %, column: phenom-
enex luna C8 (2) (250X4.6 mm), mobile phase: 90 % ace-
tonitrile in 0.1 % formic acid, flow rate: 1.0 mL/min.
1‑(2‑Hydroxy‑4‑((1‑(4‑nitrobenzyl)‑1H‑1,2,3‑triazol‑4‑yl)
methoxy)phenyl)‑2‑(4‑isobutylphenyl)propan‑1‑one (13o)
Chemical formula: C29H30N4O5; yield: 90 %; white solid; 
mp: 150–152  °C; 1H-NMR (400  MHz, CDCl3) δ 12.91 
(s, 1H), 8.24 (d, J  =  8.4  Hz, 2H), 7.73 (d, J  =  9.07  Hz, 
1H), 7.61 (s, J =  3.97  Hz, 1H), 7.45–7.39 (m, 2H), 7.28 
(s, 1H), 7.19 (d, J =  7.30  Hz, 2H), 7.10 (d, 1H), 6.49 (d, 
J =  2.49 Hz, 1H), 6.42 (dd, J =  8.98, 2.53 Hz, 1H), 5.66 
(s, J =  3.05  Hz, 2H), 5.21 (s, J =  3.99  Hz, 2H), 4.63 (q, 
J = 6.82 Hz, 1H), 2.44 (d, J = 6.00 Hz, 2H), 1.89–1.80 (m, 
1H), 1.53 (d, J = 8.49 Hz, 3H), 0.90 (d, J = 6.42 Hz, 6H); 
13C-NMR (100  MHz, CDCl3)δ 205.18, 166.37, 164.60, 
148.83, 144.88, 142.04, 141.33, 139.30, 133.07, 130.5 (2C), 
129.5 (2C), 128.0 (2C), 125.2 (2C), 123.88, 114.35, 108.58, 
103.24, 63.43, 54.77, 48.21, 46.61, 31.88, 24.21 (2C), 21.06; 
LRMS: (ES+) m/z = 515 [M + 1], 537 [M + Na]; HPLC 
99.68 %, column: phenomenex luna C8 (2) (250X4.6 mm), 





Chemical formula: C28H28BrN3O3; yield: 86  %; white 
solid; mp: 133–135  °C; 1H-NMR (400  MHz, CDCl3) δ 
12.92 (s, 1H), 8.02 (s, 1H), 7.74 (d, J = 9.07 Hz, 1H), 7.63 
(m, J = 8.98, 2.18 Hz, 4H), 7.19 (d, J = 8.02 Hz, 2H), 7.08 
(d, J = 8.00 Hz, 2H), 6.52 (d, J = 2.44 Hz, 1H), 6.45 (dd, 
J = 8.99, 2.47 Hz, 1H), 5.27 (s, 2H), 4.61 (q, J = 6.81 Hz, 
1H), 2.41 (d, J =  7.16  Hz, 2H), 1.82–1.79 (m, 1H), 1.51 
(d, J = 6.84 Hz, 3H), 0.87 (d, J = 6.59 Hz, 6H); 13C-NMR 
(101  MHz, CDCl3) δ 205.2, 166.3, 164.6, 144.9, 141.3, 
139.3, 136.5, 133.7 (2C), 133.1, 130.5 (2C), 128.1 (2C), 
123.6, 122.9 (2C), 121.8, 114.3, 108.5, 103.3, 63.3, 48.2, 
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Chemical formula: C28H28ClN3O3; yield: 83  %; white 
solid; mp: 80–82 °C; 1H-NMR (400 MHz, CDCl3) δ 12.91 
(s, 1H), 8.06 (s, 1H), 7.76 (d, J = 8.99 Hz, 1H), 7.67–7.58 
(m, 2H), 7.52–7.46 (m, 2H), 7.21 (d, J = 7.77 Hz, 2H), 7.10 
(d, J = 7.74 Hz, 2H), 6.56 (d, J = 1.86 Hz, 1H), 6.53–6.46 
(m, 1H), 5.32 (s, 2H), 4.64 (q, J = 6.73 Hz, 1H), 2.44 (d, 
J = 7.04 Hz, 2H), 1.88–1.81 (m, 1H), 1.55 (d, J = 6.72 Hz, 
3H), 0.90 (d, J  =  6.46  Hz, 6H); 13C-NMR (101  MHz, 
CDCl3) δ 205.2, 166.4, 164.7, 143.6, 141.2, 139.3, 135.5, 
133.0, 131.7, 131.6, 130.5 (2C), 129.4, 128.8, 128.6, 
128.1(2C), 125.9, 114.3, 108.6, 103.3, 63.4, 48.2, 46.6, 
31.8, 24.2 (2C), 21.0; LRMS: (ES+) m/z = 490 [M + 1], 
512 [M + Na]; HPLC 99.35 %, column: phenomenex luna 
C8 (2) (250X4.6 mm), mobile phase: 90 % acetonitrile in 
0.1 % formic acid, flow rate: 1.0 mL/min.
Biological evaluation
Animals
Wistar strain albino rats of male sex weighing 150–250 g 
were purchased from National Institute of Nutrition, 
Hyderabad, India and housed under standard environ-
mental conditions (temperature: 24  ±  1  °C, light/dark 
cycle: 10/14  h). The rats were fed with standard pellet 
diet (Amrut laboratory animal feed, Maharashtra, India) 
and water ad libitum. Animals were acclimatized to labo-
ratory conditions at least 1  week before conducting the 
experiments according to the guide lines of CPCSEA–
New Delhi (Registration No.—915/ac/05/CPCSEA).
In vivo anti‑inflammatory activity
The synthesized compounds assessed for their anti-
inflammatory activity using carrageenan-induced rat paw 
edema method. Male Wistar rats (150–250 g) were fasted 
with access of water at least 24  h prior to the experi-
ments and were divided randomly into different groups 
(control, standard and the test groups) of five rats each. 
The rat paw edema was induced by subcutaneous injec-
tion of 0.1 mL of 1 % freshly prepared saline solution of 
carrageenan into the right hind paw of rats. The stand-
ard drug ibuprofen (10 mg/kg body weight) given orally 
as a positive control. The control group was administered 
orally with 0.9  % of 0.1  mL of saline solution only. The 
test groups were administered orally with the synthe-
sized compounds at the equimolar dosage of the stand-
ard drug, 1  h before the administration of carrageenan. 
The paw volumes were measured using plethysmometer 
at interval of 1 h.
Bactericidal assay
Bacterial strains
Gram positive strains methicillin-resistant S. aureus 
(MRSA, NCTC 13616), Bacillus subtilis (ATCC 6633), 
Bacillus cereus (ATCC 14579) and gram negative strains 
Klebsiella pneumoniae (ATCC 43816), Escherichia coli 
(ATCC 8739), Proteus vulgaris (ATCC 13315) were pro-
cured from American type culture collection, USA. 
Methicillin-resistant S. aureus was purchased from cul-
ture collections, UK. All bacterial strains stored at −80 °C 
were streaked on Luria–Bertani (LB) agar plates (Hi-
media Laboratories, Mumbai, India) and incubated at 
37 °C for 20 to 24 h. A few isolated colonies were selected 
from each plate and suspended in 5  mL of LB broth in 
sterile culture vessel. The vessel was plugged with cotton 
and incubated with gentle shaking (140 rpm) at 37 °C for 
20 h.
Determination of bactericidal activity
The assay was conducted to assess the bactericidal activi-
ties of synthesized compounds through microtiter plates 
(Lambert et  al. 2001). The assay reaction mixture con-
sisted of phosphate-buffered saline (PBS) [50 mM sodium 
phosphate, 150 mM NaCl (pH 7.0)], the test compound 
at various concentrations and the bacterial strains were 
prepared in sterile 96-well microtiter plates (Nunc, Inc). 
The wells are filled with 100 µL diluted test compounds 
in PBS and 50  µL of the diluted bacterial strains. The 
wells were incubated with gentle shaking (140  rpm) at 
37 °C for various incubation periods 0 (baseline), 2, 4, 8, 
12 and 24 h (time-kill studies). For positive and negative 
controls, a separate microtiter plate was prepared and 
screened for each incubation time studied (0, 2, 4, 8, 12 
and 24  h). Following incubation, a 20-µL aliquot from 
each well was spotted at the top of a square plate con-
taining nutrient agar medium. The plate was labelled and 
tapped gently to facilitate the movement of the liquid. 
There were approximately 200 cells in the spotted (20-µL) 
sample. Plates were placed uncovered in biohood until 
the sample liquid dried (ca. 10 min) and incubated over-
night at 37 °C. The colony forming units (CFU) for each 
streak were enumerated after 24 h using a colony counter.
The number of CFU at each dilution of test compounds 
was compared with the average of positive control value 
to determine the percentage of bacteria killed per well. 
The percentage of the bacteria killed was plotted graphi-
cally, and the percentage of the test compound result-
ing decrease in the number of CFU (MIC/MBC) was 
determined.
Molecular modelling approach
In the present study, Hyperchem 8.0, Swiss Protein Data 
Base Viewer (SPDBV) 3.7 (Johansson et al. 2012) version, 
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GOLD Version 2.0, ArgusLabs 4.0.1 and Discovery stu-
dio visualiser 4.1 docking programs were evaluated to 
determine the interactions, affinities, binding energies 
and selectivity’s of compounds (13a–q). Ligands energy 
minimization was carried out by using Hyperchem. 
8.0 version. The protein–ligand interactions between 
COX-2 (PDB code 4PH9) and target molecules (13a–q) 
were prepared for docking studies by adding hydrogen 
atoms, removing water molecules, co-crystallized inhibi-
tors and refined by using the Deep View/SPDBV. Basic 
amines were protonated and acidic carboxyl groups were 
de-protonated prior to charge calculation. Then suc-
cessful docking has been performed using GOLD 2.0. 
GOLD was used to evaluate Chem score and Gold fitness 
functions. ArgusLab 4.0.1 docking software used here 
to visualize the binding conformations and to calculate 
the binding energies of the analogues (13a–q). Discov-
ery studio visualizer has been utilized to visualize the 
best binding poses of the final target analogues (13a–q) 
within the active site of 4PH9 protein.
Conclusions
We have designed and synthesized a number of hybrid 
molecules containing ibuprofen-resorcinol-triazole moi-
eties in single molecule using Click chemistry. These 
synthesized analogues (13a–q) were screened for in vivo 
anti-inflammatory. Compounds 13l, 13g, 13c, 13k, 13i, 
13n, 13m and 13j were shown significant activity. Most 
of the biological experimental values correlated with 
docking results. These molecular binding interactions of 
an in silico data demonstrated that 13o has more speci-
ficity towards the COX-2 binding site and could be a 
potent anti-inflammatory compound. These final deriva-
tives were also evaluated for bactericidal activity. Com-
pounds 13c, 13i, 13l and 13o exhibited good bactericidal 
profile. Finally, among all compounds 13o, 13c, 13i 
and 13l showed an interesting dual anti-inflammatory 
and antibacterial activity. These results gave us positive 
encouragement to develop further novel chemical enti-
ties towards challenging biological agents.
Authors’ contributions
KKA carried out the synthesis, purification of the compounds, analyzed the 
data and shared in writing the manuscript. SV have been involved in the 
purification and drafting the manuscript. RM performed the docking studies. 
MR carried out the characterization of the compounds. MKT carried out the 
biological assay. PJP designed the research, helped in the results and discus-
sion, shared in writing the manuscript and revised the manuscript. All authors 
read and approved the final manuscript.
Additional file
Additional file 1. Supplementary material (Copies of 1H-NMR, 13C-NMR, 
LRMS and HPLC) for synthesized compounds.
Author details
1 Department of Chemistry, University College of Science, Saifabad, Osmania 
University, Hyderabad, Telangana 500004, India. 2 Chaitanya College of Phar-
macy Education and Research, Kishanpura, Hanamkonda, Warangal, Telangana 
506001, India. 
Acknowledgements
KKA thanks to CSIR, New Delhi, India, for financial support in the form of senior 
research fellowship (SRF) and central facilities for research and development 
(CFRD), Osmania University, Hyderabad, India, for providing analytical support.
Competing interests
The authors declare that they have no competing interests.
Received: 22 December 2015   Accepted: 24 March 2016
References
Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI (1992) Gastrointes-
tinal damage associated with the use of nonsteroidal antiinflammatory 
drugs. N Engl J Med 327:749–754
Alsarra IA, Ahmed MO, Alanazi FK, ElTahir KEH, Alsheikh AM, Neau SH (2010) 
Influence of cyclodextrin complexation with NSAIDs on NSAID/cold 
stress-induced gastric ulceration in rats. Int J Med Sci 7:232
Bansal Y, Kaur M, Silakari O (2015) Benzimidazole–ibuprofen/mesalamine 
conjugates: potential candidates for multifactorial diseases. Eur J Med 
Chem 89:671–682
Dunn G, Hoover J, Berges D, Taggart J, Davis L, Dietz E, Jakas D, Yim N, Actor P, 
Uri J (1976) Orally active 7-phenylglycyl cephalosporins. Structure-activity 
studies related to cefatrizine (SK&F 60771). J Antibiot 29:65–80
Guo L, Ye C, Chen W, Ye H, Zheng R, Li J, Yang H, Yu X, Zhang D (2008) Anti-
inflammatory and analgesic potency of carboxyamidotriazole, a tumor-
ostatic agent. J Pharmacol Exp Ther 325:10–16
Haftchenary S, Jouk AO, Aubry I, Lewis AM, Landry M, Ball DP, Shouksmith AE, 
Collins CV, Tremblay ML, Gunning PT (2015) Identification of bidentate 
salicylic acid inhibitors of PTP1B. ACS Med Chem Lett 6:982–986
Johansson MU, Zoete V, Michielin O, Guex N (2012) Defining and searching for 
structural motifs using DeepView/Swiss-PdbViewer. BMC Bioinformatics 
13:173
Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP, 
Marnett LJ (2000a) Biochemically based design of cyclooxygenase-2 
(COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory 
drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci 
USA 97:925–930
Kalgutkar AS, Marnett AB, Crews BC, Remmel RP, Marnett LJ (2000b) Ester and 
amide derivatives of the nonsteroidal antiinflammatory drug, indometha-
cin, as selective cyclooxygenase-2 inhibitors. J Med Chem 43:2860–2870
Kalgutkar AS, Rowlinson SW, Crews BC, Marnett LJ (2002) Amide derivatives of 
meclofenamic acid as selective cyclooxygenase-2 inhibitors. Bioorg Med 
Chem Lett 12:521–524
Kumar D, Khare G, Kidwai S, Tyagi AK, Singh R, Rawat DS (2014) Synthesis of 
novel 1,2,3-triazole derivatives of isoniazid and their in vitro and in vivo 
antimycobacterial activity evaluation. Eur J Med Chem 81:301–313
Lambert R, Skandamis PN, Coote PJ, Nychas GJ (2001) A study of the minimum 
inhibitory concentration and mode of action of oregano essential oil, 
thymol and carvacrol. J Appl Microbiol 91:453–462
Lazzaroni M, Bianchi Porro G (2004) Gastrointestinal side-effects of traditional 
non-steroidal anti-inflammatory drugs and new formulations. Aliment 
Pharmacol Ther 20:48–58
Lee JH, Gupta S, Jeong W, Rhee YH, Park J (2012) Characterization and utility 
of N-unsubstituted imines synthesized from alkyl azides by ruthenium 
catalysis. Angew Chem Int Ed 51:10851–10855
Liang SH, Southon AG, Fraser BH, Krause-Heuer AM, Zhang B, Shoup TM, Lewis 
R, Volitakis I, Han Y, Greguric I, Bush AI, Vasdev N (2015) Novel fluorinated 
8-hydroxyquinoline based metal ionophores for exploring the metal 
hypothesis of Alzheimer’s disease. ACS Med Chem Lett 6:1025–1029
Page 15 of 15Angajala et al. SpringerPlus  (2016) 5:423 
Liu Y, Yan W, Chen Y, Petersen JL, Shi X (2008) Efficient synthesis of 
N-2-aryl-1,2,3-triazole fluorophores via post-triazole arylation. Org Lett 
10:5389–5392
Mishra A, Veerasamy R, Jain PK, Dixit VK, Agrawal RK (2008) Synthesis, 
characterization and pharmacological evaluation of amide prodrugs of 
ketorolac. Eur J Med Chem 43:2464–2472
Orlando BJ, Lucido MJ, Malkowski MG (2015) The structure of ibuprofen bound 
to cyclooxygenase-2. J Struct Biol 189:62–66
Rao PS, Kurumurthy C, Veeraswamy B, Kumar GS, Poornachandra Y, Kumar CG, 
Vasamsetti SB, Kotamraju S, Narsaiah B (2014) Synthesis of novel 1,2,3-tria-
zole substituted-N-alkyl/aryl nitrone derivatives, their anti-inflammatory 
and anticancer activity. Eur J Med Chem 80:184–191
Romeo E, Ponzano S, Armirotti A, Summa M, Bertozzi F, Garau G, Bandiera 
T, Piomelli D (2015) Activity-based probe for N-acylethanolamine acid 
amidase. ACS Chem Biol 10:2057–2064
Rostovtsev VV, Green LG, Fokin VV, Sharpless KB (2002) A stepwise huisgen 
cycloaddition process: copper(I)-catalyzed regioselective “ligation” of 
azides and terminal alkynes. Angew Chem Int Ed 41:2596–2599
Ruiz J, Lowenthal D (1997) NSAIDS and nephrotoxicity in the elderly. Geriatr 
Nephrol Urol 7:51–57
Shafi S, Alam MM, Mulakayala N, Mulakayala C, Vanaja G, Kalle AM, Pallu 
R, Alam M (2012) Synthesis of novel 2-mercapto benzothiazole and 
1,2,3-triazole based bis-heterocycles: their anti-inflammatory and anti-
nociceptive activities. Eur J Med Chem 49:324–333
Shanbhag VR, Crider AM, Gokhale R, Harpalani A, Dick RM (1992) Ester and 
amide prodrugs of ibuprofen and naproxen: synthesis, anti-inflammatory 
activity, and gastrointestinal toxicity. J Pharm Sci 81:149–154
Tan H, Ong W, Lai S, Chow W (2007) Nimesulide-induced hepatotoxicity and 
fatal hepatic failure. Singapore Med J 48:582–585
Thompson M (2004) Molecular docking using ArgusLab, an efficient shape-
based search algorithm and the AScore scoring function. In ACS meeting, 
Philadelphia, p 42
Tornøe CW, Christensen C, Meldal M (2002) Peptidotriazoles on solid phase: 
[1,2,3]-triazoles by regiospecific copper(I)-catalyzed 1,3-dipolar cycloaddi-
tions of terminal alkynes to azides. J Org Chem 67:3057–3064
Tozkoparan B, Gökhan N, Aktay G, Yeşilada E, Ertan M (2000) 6-Benzylidenethia-
zolo [3,2-b]-1,2,4-triazole-5 (6 h)-onessubstituted with ibuprofen: 
synthesis, characterizationand evaluation of anti-inflammatory activity. 
Eur J Med Chem 35:743–750
Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD (2003) Improved 
protein-ligand docking using GOLD. Proteins Struct Funct Bioinform 
52:609–623
Wacharasindhu S, Bardhan S, Wan Z-K, Tabei K, Mansour TS (2009) Oxidative 
palladium catalysis in SNAr reactions leading to heteroaryl ethers from 
pyridotriazol-1-yloxy heterocycles with aryl boronic acids. J Am Chem 
Soc 131:4174–4175
Winter CA, Risley EA, Nuss GW (1962) Carrageenin-induced edema in hind 
paw of the rat as an assay for antiinflammatory drugs. Exp Biol Med 
111:544–547
Yadav MR, Nimekar DM, Ananthakrishnan A, Brahmkshatriya PS, Shirude ST, 
Giridhar R, Parmar A, Balaraman R (2006) Synthesis of new chemical 
entities from paracetamol and NSAIDs with improved pharmacodynamic 
profile. Bioorg Med Chem 14:8701–8706
Yang Y, Rasmussen BA, Shlaes DM (1999) Class A β-lactamases—enzyme-
inhibitor interactions and resistance. Pharmacol Ther 83:141–151
